Wolff-Parkinson-White syndrome medical therapy
|
Wolff-Parkinson-White syndrome Microchapters |
|
Differentiating Wolff-Parkinson-White syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wolff-Parkinson-White syndrome medical therapy On the Web |
|
Risk calculators and risk factors for Wolff-Parkinson-White syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Rim Halaby, M.D. [3]
Overview
WPW syndrome patients with AVRT who are hemodynamically unstable, as reflected by the presence of hypotension, cold extremities, mottling or peripheral cyanosis, or those who present with ischemic chest pain or decompensated heart failure should urgently undergo direct current cardioversion.[1] The medical therapy of hemodynamically stable patients with WPW syndrome depends on the type of the tachycardia. When the ECG findings suggest orthodromic AVRT, the patient should be managed similarly to patients with supreventricular tachycardia followed by the sequential administration of adenosine, verapamil and procainamide in case of failure to improve. Among patients with antidromic AVRT, AV nodal blocking agents should be avoided and patients should be treated with either procainamide, ibutilide or flecainide.[2] In case of WPW syndrome with atrial fibrillation in hemodynamically stable patients, procainamide, ibutilide or flecainide can be administered.[3] The long term treatment of patients with WPW syndrome depends on the presence or absence of symptoms and their severity. Patients who have poorly tolerated symptomatic WPW syndrome should undergo [[catheter ablation.[2]
Acute Treatment
Atrioventricular Reentrant Tachycardia (AVRT)
- AVRT is one of the type of tachycardia that can occur in patients with WPW pattern. AVRT can be either orthodromic or antidromic, and the distinction between the two types is important because it dictates the choice of treatment.
Hemodynamically Unstable Patients
- WPW syndrome patients with AVRT who are hemodynamically unstable, as reflected by the presence of hypotension, cold extremities, mottling or peripheral cyanosis, or those who present with ischemic chest pain or decompensated heart failure should urgently undergo direct current cardioversion. The shocks should be delivered as follows:
- Narrow regular rhythm: synchronized electrical cardioversion, 50-100 Joules
- Narrow irregular rhythm: synchronized electrical cardioversion, 120-200 Joules biphasic or 200 Joules monophasic
- Wide regular rhythm: synchronized electrical cardioversion, 100 Joules
- Wide irregular rhythm: unsynchronized electrical cardioversion, 200-360 Joules monophasic, or 100-200 Joules biphasic[1]
Orthodromic AVRT in Hemodynamically Stable Patients
- The management of WPW syndrome patients who are hemodynamically stable depends on the type of AVRT. When the ECG findings suggest orthodromic AVRT, the patient should be managed similarly to patients with supreventricular tachycardia. The management should begin with vagal maneuvers such as carotid sinus massage and valsalva maneuver. If the patient's tachycardia does not resolve, the patient should be administered IV adenosine. In case of failure to improve, administration of verapamil must be considered followed by procainamide.[2]
Antidromic AVRT in Hemodynamically Stable Patients
- Among patients with antidromic AVRT, AV nodal blocking agents should be avoided because the antegrade impulses are occurring through the accessory pathway and not through the AV node. In this case, the use of digoxin, calcium channel blockers, beta blockers and adenosine should be avoided. Patients should be treated with either procainamide, ibutilide or flecainide.[2]
Atrial Fibrillation
- WPW syndrome with atrial fibrillation should be suspected whenever the ECG reveals an irregular rhythm with absent P wave in the presence of a heart rate more than 220 beats per minute.
Hemodynamically Unstable Patients
In hemodynamically unstable patients, urgent direct current cardioversion should be performed.[1]
Hemodynamically Stable Patients
- Hemodynamically stable patients can be administered any of the following intravenous medications:
- Procainamide (Class I, Level of evidence C)
- Ibutilide (Class I, Level of evidence C)
- Flecainide (Class IIa, Level of evidence B)
- Quinidine (Class IIb, Level of evidence B)
- Procainamide (Class IIb, Level of evidence B)
- Disopyramide (Class IIb, Level of evidence B)
- Ibutilide (Class IIb, Level of evidence B)
- Amiodarone(Class IIb, Level of evidence B)[3]
Long Term Management
The long term management of patients with WPW syndrome depends on the presence or absence of syndrome. Among symptomatic patients, the tolerability of the symptoms guides the choice of the long term treatment.[2]
Asymptomatic Patients
- Asymptomatic patients can either receive no treatment (Class I, Level of Evidence C) or can undergo catheter ablation (Class IIa, Level of Evidence B).[2]
Symptomatic Patients
- Patients who have poorly tolerated symptoms or atrial fibrillation with rapid conduction should be treated with catheter ablation (Class I, Level of Evidence B).[2]
- Patients who have well tolerated symptoms can be treated with any of the following:
- AV nodal blocking agents such as digoxin, verapamil and dialtizem should not be administered to patients with WPW syndrome and atrial fibrillation (Class III, Level of Evidence C).[2]
References
- ↑ 1.0 1.1 1.2 "Part 8: Adult Advanced Cardiovascular Life Support". Retrieved 3 April 2014.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.
- ↑ 3.0 3.1 American College of Cardiology Foundation. American Heart Association. European Society of Cardiology. Heart Rhythm Society. Wann LS, Curtis AB; et al. (2013). "Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines". Circulation. 127 (18): 1916–26. doi:10.1161/CIR.0b013e318290826d. PMID 23545139.